David M Schuster1, Cristina Nanni2, Stefano Fanti2, Shuntaro Oka3, Hiroyuki Okudaira3, Yusuke Inoue4, Jens Sörensen5, Rikard Owenius6, Peter Choyke7, Baris Turkbey7, Trond V Bogsrud8, Tore Bach-Gansmo9, Raghuveer K Halkar10, Jonathon A Nye10, Oluwaseun A Odewole10, Bital Savir-Baruch10, Mark M Goodman10. 1. Department of Radiology and Imaging Sciences, Emory University, Atlanta, Georgia dschust@emory.edu. 2. Department of Nuclear Medicine, Policlinico S. Orsola, University of Bologna, Bologna, Italy. 3. Research Center, Nihon Medi-Physics Co., Ltd., Chiba, Japan. 4. Department of Diagnostic Radiology, Kitasato University School of Medicine, Kitasato, Japan. 5. Department of Radiology, Oncology and Radiation Sciences, Uppsala University, Uppsala, Sweden. 6. GE Healthcare, Life Sciences, Imaging R&D, Uppsala, Sweden. 7. Molecular Imaging Program, National Cancer Institute, Bethesda, Maryland. 8. Department of Radiology and Nuclear Medicine, Oslo University Hospital, Oslo, Norway; and Department of Nuclear Medicine and PET-Center, Aarhus University Hospital, Aarhus, Denmark. 9. Department of Radiology and Nuclear Medicine, Oslo University Hospital, Oslo, Norway; and. 10. Department of Radiology and Imaging Sciences, Emory University, Atlanta, Georgia.
Abstract
UNLABELLED: Anti-1-amino-3-(18)F-fluorocyclobutane-1-carboxylic acid ((18)F-FACBC) is a synthetic amino acid analog PET radiotracer undergoing clinical trials for the evaluation of prostate and other cancers. We aimed to describe common physiologic uptake patterns, incidental findings, and variants in patients who had undergone (18)F-FACBC PET. METHODS: Sixteen clinical trials involving 611 (18)F-FACBC studies from 6 centers, which included dosimetry studies on 12 healthy volunteers, were reviewed. Qualitative observations of common physiologic patterns, incidental uptake, and variants that could simulate disease were recorded and compared with similar observations in studies of the healthy volunteers. Quantitative analysis of select data and review of prior published reports and observations were also made. RESULTS: The liver and pancreas demonstrated the most intense uptake. Moderate salivary and pituitary uptake and variable mild to moderate bowel activity were commonly visualized. Moderate bone marrow and mild muscle activity were present on early images, with marrow activity decreasing and muscle activity increasing with time. Brain and lungs demonstrated activity less than blood pool. Though (18)F-FACBC exhibited little renal excretion or bladder uptake during the clinically useful early imaging time window, mild to moderate activity might accumulate in the bladder and interfere with evaluation of adjacent prostate bed and seminal vesicles in 5%-10% of patients. Uptake might also occur from benign processes such as infection, inflammation, prostatic hyperplasia, and metabolically active benign bone lesions such as osteoid osteoma. CONCLUSION: Common physiologic uptake patterns were similar to those noted in healthy volunteers. The activity in organs followed the presence of amino acid transport and metabolism described with other amino acid-based PET radiotracers. As with other PET radiotracers such as (18)F-FDG, focal nonphysiologic uptake may represent incidental malignancy. Uptake due to benign etiologies distinct from physiologic background also occurred and could lead to misinterpretations if the reader is unaware of them.
UNLABELLED: Anti-1-amino-3-(18)F-fluorocyclobutane-1-carboxylic acid ((18)F-FACBC) is a synthetic amino acid analog PET radiotracer undergoing clinical trials for the evaluation of prostate and other cancers. We aimed to describe common physiologic uptake patterns, incidental findings, and variants in patients who had undergone (18)F-FACBC PET. METHODS: Sixteen clinical trials involving 611 (18)F-FACBC studies from 6 centers, which included dosimetry studies on 12 healthy volunteers, were reviewed. Qualitative observations of common physiologic patterns, incidental uptake, and variants that could simulate disease were recorded and compared with similar observations in studies of the healthy volunteers. Quantitative analysis of select data and review of prior published reports and observations were also made. RESULTS: The liver and pancreas demonstrated the most intense uptake. Moderate salivary and pituitary uptake and variable mild to moderate bowel activity were commonly visualized. Moderate bone marrow and mild muscle activity were present on early images, with marrow activity decreasing and muscle activity increasing with time. Brain and lungs demonstrated activity less than blood pool. Though (18)F-FACBC exhibited little renal excretion or bladder uptake during the clinically useful early imaging time window, mild to moderate activity might accumulate in the bladder and interfere with evaluation of adjacent prostate bed and seminal vesicles in 5%-10% of patients. Uptake might also occur from benign processes such as infection, inflammation, prostatic hyperplasia, and metabolically active benign bone lesions such as osteoid osteoma. CONCLUSION: Common physiologic uptake patterns were similar to those noted in healthy volunteers. The activity in organs followed the presence of amino acid transport and metabolism described with other amino acid-based PET radiotracers. As with other PET radiotracers such as (18)F-FDG, focal nonphysiologic uptake may represent incidental malignancy. Uptake due to benign etiologies distinct from physiologic background also occurred and could lead to misinterpretations if the reader is unaware of them.
Authors: Emilio Bombardieri; Cumali Aktolun; Richard P Baum; Angelika Bishof-Delaloye; John Buscombe; Jean François Chatal; Lorenzo Maffioli; Roy Moncayo; Luc Mortelmans; Sven N Reske Journal: Eur J Nucl Med Mol Imaging Date: 2003-12 Impact factor: 9.236
Authors: David M Schuster; John R Votaw; Peter T Nieh; Weiping Yu; Jonathon A Nye; Viraj Master; F DuBois Bowman; Muta M Issa; Mark M Goodman Journal: J Nucl Med Date: 2007-01 Impact factor: 10.057
Authors: Jonathan McConathy; Weiping Yu; Nachwa Jarkas; Wonewoo Seo; David M Schuster; Mark M Goodman Journal: Med Res Rev Date: 2011-07-26 Impact factor: 12.944
Authors: Rianot Amzat; Pooneh Taleghani; Daniel L Miller; Jonathan J Beitler; Leah M Bellamy; Jonathon A Nye; Weiping Yu; Bital Savir-Baruch; Adeboye O Osunkoya; Zhengjia Chen; William F Auffermann; Mark M Goodman; David M Schuster Journal: Mol Imaging Biol Date: 2013-10 Impact factor: 3.488
Authors: Baris Turkbey; Esther Mena; Joanna Shih; Peter A Pinto; Maria J Merino; Maria L Lindenberg; Marcelino Bernardo; Yolanda L McKinney; Stephen Adler; Rikard Owenius; Peter L Choyke; Karen A Kurdziel Journal: Radiology Date: 2013-11-08 Impact factor: 11.105
Authors: Jonathon A Nye; David M Schuster; Weiping Yu; Vernon M Camp; Mark M Goodman; John R Votaw Journal: J Nucl Med Date: 2007-05-15 Impact factor: 10.057
Authors: F I Tade; W G Wiles; G Lu; B Bilir; O Akin-Akintayo; J S Lee; D Patil; W Yu; C Ormenisan Gherasim; B Fei; C S Moreno; A O Osunkoya; E J Teoh; S Oka; H Okudaira; M M Goodman; D M Schuster Journal: Amino Acids Date: 2018-06-15 Impact factor: 3.520
Authors: Barbara J Amorim; Vinay Prabhu; Sara S Marco; Debra Gervais; Willian E Palmer; Pedram Heidari; Mark Vangel; Philip J Saylor; Onofrio A Catalano Journal: Eur J Nucl Med Mol Imaging Date: 2019-09-06 Impact factor: 9.236